 I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, will be presenting preclinical data on a newly developed, novel asset TJ-CD4B, at the American Association for Cancer Research AACR Virtual Annual Meeting II on June 22-24, 2020. 